Incannex Healthcare (IXHL) Issues Q1 Quarterly Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Incannex Healthcare Inc. Quarterly Update, Q1 2024
April 16, 2024 8:02 AM EDTMELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (Incannex or the Company), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
Incannex is undertaking various U.S. Food and Drug Administration (FDA) research and development (R&D) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies. The nearest-to-market projects in the Companys therapeutic pipeline are:
IHL-42X drug candidate for Obstructive Sleep Apnea (OSA) - Phase 2/3 studies... More